Several ALS Patients See Remarkable Response to ASO Treatment

3 questions for ALS expert Dr. Qiang Zhu – Van Andel Institute

Amyotrophic lateral sclerosis (ALS) is a progressive disorder that damages movement-regulating nerve cells (neurons) in the brain and spinal cord. As more of these neurons degenerate and die, people experience […] Van Andel Institute - Van Andel Institute transforms human health through groundbreaking biomedical research and cutting-edge science education.

ALS Network collaborates on $300K drug-repurposing study

The ALS Network will support a collaborative research effort, at California’s Lawrence Livermore National Laboratory, that will use electronic health records (EHRs) to identify existing medications that could slow the progression of amyotrophic lateral sclerosis (ALS). The $300,000 project is aimed at drug repurposing — finding medications already approved for other conditions that may have off-target effects beneficial in ALS. Because these the…

Several ALS Patients See Remarkable Response to ASO Treatment

Typically, the goal of ALS treatments is to slow the disease or halt progression. But new data from the antisense oligonucleotide (ASO) jacifusen for FUS-ALS show that two patients went beyond the expected, and showed improvements. “When testing new drugs for ALS, we do not expect to see clinical improvement,” said Neil Shneider, MD, PhD, director of the Eleanor and Lou Gehrig ALS Center and associate professor of motor neuron disorders at Colum…